Short-Term ADT does not improve radiotherapy-associated survival in prostate cancer

Adding short-term androgen deprivation therapy to radiotherapy does not improve overall survival among men with intermediate-risk prostate cancer, according to data from the prospective, randomised phase 3 PCS III clinical trial, presented during the 2015 Genitourinary Cancers Symposium.

Prostate Cancer Advisor